口服伊科托金拉用于成人和青少年的斑块性牛皮
Robert Bissonnette1, Jennifer Soung2,3, Adelaide A Hebert4
1Innovaderm Research, Montreal.
The New England journal of medicine
|November 5, 2025
概括
与安慰剂相比,Icotrokinra是一种口服,准了介质素-23,在患有斑块牛皮的成人和青少年中显著改善了皮肤清除. 这种向治疗在第三阶段试验中显示出有效性,为患者提供了新的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 斑块性牛皮是一种慢性自身免疫性疾病.
- 介质素-23 (IL-23) 途径是牛皮治疗的关键标.
- 伊科特罗金拉是一种选择性向IL-23受体的口服.
研究的目的:
- 评估icotrokinra在中度至重度斑块性牛皮的疗效和安全性.
- 为了比较icotrokinra与安慰剂在实现皮肤清除和减少疾病严重程度方面.
主要方法:
- 第三阶段,双盲,随机,安慰剂对照试验.
- 涉及的成人和青少年 (≥12岁) 患有中度至重度的斑块性牛皮.
- 共同初级终点:研究人员的全球评估 (IGA) 0/1反应和牛皮区域和严重性指数 (PASI) 90反应在第16周.
主要成果:
- 65%的icotrokinra获得IGA 0/1反应,而安慰剂获得8% (P<0.001).
- 50%的icotrokinra获得了PASI 90响应,而安慰剂的4% (P<0.001).
- 完整的皮肤清除 (IGA 0或PASI 100) 显著高于icotrokinra.
结论:
- 选择性IL-23受体阻塞与icotrokinra显著改善了皮肤清除在斑块牛皮.
- 伊科特罗金拉在中度至重度的斑块性牛皮症中显示出有前途的疗效.
- 需要进一步的数据来进行完整的利益风险评估.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
450
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
450
01:29Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
01:29Drugs for Treatment of Ulcerative Colitis in IBD
448
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
448
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
423
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
423